Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TNS4 |
| Gene Name: | TNS4 |
| Protein Full Name: | Tensin-4 |
| Alias: | C terminal tensin like; CTEN; C-terminal tensin-like; C-terminal tensin-like protein; TENS4; Tensin 4; Tensin-4 |
| Mass (Da): | 76764 |
| Number AA: | 715 |
| UniProt ID: | Q8IZW8 |
| Locus ID: | 84951 |
| COSMIC ID: | TNS4 |
| Gene location on chromosome: | 17q21.2 |
| Cancer protein type: | OP/TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 19750 |
| Percent of cancer specimens with mutations: | 0.68 |
| Normal role description: | TNS4 (CTEN) may be involved in cell migration, cartilage development and in linking signal transduction pathways to the cytoskeleton, as well as in promoting apoptosis, via its cleavage by caspase-3. Studies have shown that CTEN may be an upstream regulator of ILK, and a down-stream target of KRas. Its expression is down-regulated in prostate cancer, but up-regulated in numerous other malignancies such as breast-, colon-, gastric and lung cancers, and potentially in melanoma*, suggesting that its role in tumorigenesis is tissue-dependent. |
| Commentary on involvement of protein in cancer: | Only 2 ovarian- and 1 melanoma samples were included in Sanger COSMIC. 1/44 CNS samples was also mutated. *Note: The role of TNS4/CTEN in melanoma is currently being investigated (by me) and early results indicate that it may be acting as an oncoprotein in melanoma. |